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Abstract
Background: The formation of destructive hypercellular pannus is critical to joint damage in rheumatoid arthritis
(RA). The collagen triple helix repeat containing 1 (CTHRC1) protein expressed by activated stromal cells of diverse
origin has previously been implicated in tissue remodeling and carcinogenesis. We recently discovered that the
synovial Cthrc1 mRNA directly correlates with arthritis severity in mice. This study characterizes the role of CTHRC1
in arthritic pannus formation.
Methods: Synovial joints of mice with collagen antibody-induced arthritis (CAIA) and human RA-fibroblast-like
synoviocytes (FLS) were immunostained for CTHRC1, FLS and macrophage-specific markers. CTHRC1 levels in
plasma from patients with RA were measured using sandwich ELISA. The migratory response of fibroblasts was
studied with a transwell migration assay and time-lapse microscopy. Velocity and directness of cell migration was
analyzed by recording the trajectories of cells treated with rhCTHRC1.
Results: Immunohistochemical analysis of normal and inflamed synovium revealed highly inducible expression of
CTHRC1 in arthritis (10.9-fold). At the tissue level, CTHRC1-expressing cells occupied the same niche as large
fibroblast-like cells positive for α-smooth muscle actin (α-SMA) and cadherin 11 (CDH11). CTHRC1 was produced
by activated FLS predominantly located at the synovial intimal lining and at the bone-pannus interface. Cultured
RA-FLS expressed CDH11, α-SMA, and CTHRC1. Upon treatment with exogenous rhCTHRC1, embryonic fibroblasts
and RA-FLS significantly increased migration velocity, directness, and cell length along the front-tail axis (1.4-fold,
p < 0.01).
Conclusion: CTHRC1 was established as a novel marker of activated synoviocytes in murine experimental arthritis
and RA. The pro-migratory effect of CTHRC1 on synoviocytes is considered one of the mechanisms promoting
hypercellularity of the arthritic pannus.
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Background
Hypertrophy of the synovial membrane accompanied by
increased production of cartilage-degrading and bone-
degrading enzymes is a hallmark of arthritis. Triggered by
local inflammation in the synovial joint, normal fibroblast-
like synoviocytes (FLS) are substituted with newly formed
hypercellular granulation tissue, the pannus. Hypercellu-
larity of the pannus could be explained by the proliferation
of synovial intimal lining cells, but the pannus is largely
formed by immigration into the synovium hematopoietic
and mesenchymal precursors. The latter cell lineage gives
rise to the phenotype of activated FLS [1, 2].
In addition to the increased proliferation and production
of a wide spectrum of cartilage-degrading proteases, acti-
vated FLS demonstrate a high level of invasiveness and mo-
tility within the affected joint, and FLS are even capable of
spreading the disease to as yet unaffected cartilage using
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vasculature-independent routes [3]. Invasive properties of
activated FLS from patients with rheumatoid arthritis (RA)
and from murine arthritis models directly correlate with
the rate of joint destruction and deformities, and poor dis-
ease outcome [4]. In that regard, FLS are similar to invasive
tumor cells: FLS accumulate somatic mutations in the p53
tumor suppressor gene and acquire an activated expression
status of several oncogenes that altogether contribute to
the pathological FLS phenotype [2, 5].
Activated FLS express a number of markers, but none
of them alone could be called completely specific for
FLS. One of the relatively unique surface markers for
RA-FLS is cadherin-11 (CDH11), which plays an essen-
tial role in the acquisition of the invasive phenotype of
activated FLS in arthritis [2, 6]. However, CDH11 is
expressed in many other mesenchymal-type cells and is
involved in the regulation of invasiveness of, for in-
stance, prostate and glioblastoma tumors, and also pro-
motes bone metastasis [7, 8].
Recently, we found that the expression of collagen
triple helix repeat containing 1 (CTHRC1) encoding
gene was strongly associated with the severity of murine
collagen antibody-induced arthritis (CAIA) [9]. When
CAIA is genetically attenuated by the Pgia8 locus in
BALB/c.DBA/2-Pgia8 congenic mice, expression of
Cthrc1 is decreased along with expression of mRNAs of
metalloproteinase Adamts12 and wingless (WNT)-
associated pathway members r-spondyn 2 and syndecan 2.
CTHRC1 protein is expressed in a number of embry-
onic and neonate tissues, including developing cartilage
and bone [10]. Experiments with gene-deficient and
transgenic mice indicate that CTHRC1 regulates osteo-
blastic bone formation [11]. CTHRC1 can inhibit
Smad2/3 phosphorylation after stimulation by trans-
forming growth factor (TGF)-ß and can reduce produc-
tion of collagen types I and III [12]. Overexpression of
Cthrc1 in smooth muscle cells and embryonic fibroblasts
correlates with increased cell migration properties [13].
The endogenous expression of CTHRC1 has been found
in more than a dozen types of metastatic solid cancer,
and the inhibition of CTHRC1 expression results in de-
creased cell migration in vitro [14]. Immunohistochemi-
cal analysis of various human primary cancers and
metastases has revealed that CTHRC1 expression is
actually limited to the stromal cells of solid tumors
[15, 16]. In this study, we analyzed CTHRC1 expression in
synovium and established this protein as a novel marker




Biological samples were obtained under a protocol ap-
proved by the Institutional Research Ethics Committee
(IREC) of Nazarbayev University, Astana, Kazakhstan. All
subjects gave written informed consent. Patients coming
to outpatient facility of the Republican Diagnostics Centre
(RDC, Astana, Kazakhstan), who presented with clinically
apparent synovial swelling were examined for RA symp-
toms. The final diagnostic outcome was based on persist-
ent inflammatory arthritis, magnetic resonance imaging
(MRI), radiographic analysis, disease duration, and
number of tender and swollen joints, and resulted in the
28-joint-count disease activity score (DAS28). Clinical as-
sessment was accompanied with peripheral blood analysis
for complete blood counts with differential, C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR),
rheumatoid factor (RF), and anti-citrullinated protein anti-
bodies (ACPA). Venous blood was collected into heparin-
ized tubes, and cells were removed by centrifugation at
1000 × g for 10 minutes. Plasma was stored at –80 °C.
ELISA for CTHRC1
Sandwich ELISA was used to quantify CTHRC1 in human
plasma according to the manufacturer’s protocol
(www.mmcri.org/antibody, Maine Medical Center Research
Institute, Scarborough, ME, USA). Briefly, 96-well plates
(Maxisorp, Nunc) were coated overnight at 4 °C with cap-
ture antibody 13E09 at 1.8 μg/ml in carbonate-bicarbonate
buffer pH 9.4. All subsequent procedures were performed
at room temperature. The next day, wells were washed
twice with PBS containing 0.1 % BSA and 0.1 % Tween 20
(buffer PBS-BT) and then blocked with PBS-BT for 1 hour.
Human plasma or conditioned media were diluted at least
1:5 in PBS-BT and incubated with absorbed capture anti-
bodies for 2 hours. Subsequently, the wells were washed
and then incubated with biotinylated detection antibody
Vli10G07 diluted 1:500 in PBS-BT for 1 hour. After wash-
ing, wells were treated for 1 hour with streptavidin conju-
gated with horseradish peroxidase (St-HRP) (Pierce High
Sensitivity St-HRP, Thermo Fisher Scientific Inc., Waltham,
MA, USA) diluted at 1:8,000 in PBS-BT. After the final
wash, TMB (3,3′,5,5′-tetramethylbenzidine) chromogenic
substrate (Amresco, Solon, OH, USA) was added, and the
developed signal was measured at 450 nm using the
Multiscan-FC plate reader (Thermo Fisher Scientific Inc.,
Waltham, MA, USA). Absorbance was converted to abso-
lute concentration using rhCTHRC1 as a reference. ELISA
was performed in triplicates.
Animals and arthritis induction
Mice were housed in a specific pathogen-free environ-
ment in the Institute for Animal Studies at the Albert
Einstein College of Medicine, Bronx, NY, USA. All
animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Albert
Einstein College of Medicine. Inbred BALB/c female
mice, 2–4 months old (Charles River, Wilmington, MA,
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USA) were injected with ArthritoMab antibody cocktail
(MD Biosciences Inc., St.Paul, MN, USA) according to
the manufacturer’s protocol. Briefly, mice were injected
intraperitoneally (i.p.) with 2 mg/mouse of antibodies on
day 0 followed by i.p. injection of 40 μg of lipopolysac-
charide (LPS) on day 3. Arthritis in the (FVB/N × BALB/c)
F1 hybrid mice was induced similarly, but using CIA-
MAB-2C ArthritoMab Cocktail (MD Biosciences Inc.),
which was developed for murine strains that are refractory
to arthritis. Mice were observed once or twice a day for
paw swelling and redness by two independent observers.
The arthritis scoring system was based on the number of
inflamed joints in each paw producing a total score
of 0–60 per mouse, as described previously [9, 17].
Real-time PCR
Total RNA was isolated from mouse paws using the
RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA) ac-
cording to the manufacturer’s instructions. Paw tissue
was taken from digits to the ankle or to the distal ra-
dius/ulna. RNA integrity and quality was tested on an
Agilent 2100 Bioanalyzer. The Superscript First-Strand
Synthesis kit (Invitrogen Life Technologies, Grand Island,
NY, USA) was used to generate cDNA that was assayed
using an Applied Biosystems 7900HT Fast Real-Time PCR
System. Expression was measured in triplicates and at
least two repeats using the Fast SYBR Green system
(Applied Biosystems by Life Technologies, Grand Island,
NY, USA). Cthrc1-specific primers were forward 5′-
GGGATGGATTCAAAGGGGAAA-3′ and reverse 5′-
AGAACTCGCAGAGCACTGTT-3′. Gapdh-specific
primers were forward 5′-ACCCAGAAGACTGTGGAT
GG-3′ and reverse 5′-ACACATTGGGGGTAGGAACA-
3′. Relative RNA concentration was calculated using the
delta-delta cycle threshold (Ct) method corrected for PCR
efficiency, as described previously [9, 18].
Cell lines
Human RA-FLS derived from the inflamed synovial tis-
sue of patients with RA (Cell Applications Inc., San
Diego, CA, USA) were used at passages three to four.
RA-FLS were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) with GlutaMAX-1, 4.5 g/l D-glucose,
and 25 mM HEPES, antibiotic and antimycotic (Gibco
by Life Technologies, Grand Island, NY, USA) supple-
mented with 10 % heat-inactivated FBS and growth sup-
plements (Cell Applications Inc., San Diego, CA, USA).
Mouse embryonic fibroblast cell lines C3H/10T1/2 and
NIH 3T3, and human skin fibroblast line Hs68 (all lines
from ATCC Inc., Manassas, VA, USA) were studied.
Histopathology and immunohistochemical analysis (IHC)
Mice were killed by CO2 inhalation according to the ap-
proved IACUC protocol. For histopathological analysis,
hind limbs from the digits to femur, including the knee
joint, were collected. Tissues were fixed in 10 % neutral
buffered formalin, decalcified using Immunocal reagent
(Decal Chemical Corporation, Suffern, NY, USA) and
embedded in paraffin. Tissues were sectioned at a thick-
ness of 5 μm and stained with hematoxylin-eosin or
alcian blue and nuclear fast red for histological confirm-
ation of arthritis.
For immunohistochemical analysis, sections were
deparaffinized and pretreated with 10 mM sodium cit-
rate buffer at pH 6.0 heated to 96 °C for 20 minutes for
antigen retrieval. Endogenous peroxidase activity was
quenched by incubation in 0.3 % hydrogen peroxide in
PBS for 5 minutes. Nonspecific binding was blocked for
1 hour at room temperature using 2 % BSA (Sigma-
Aldrich, St. Louis, MO, USA) and 2 % normal goat serum
(Vector laboratories Inc., Burlingame, CA, USA) in PBS
and 0.05 % Tween-20 (PBS-T buffer). For detection of
FLS-specific and macrophage-specific markers in arthritic
pannus, we used rabbit anti-CTHRC1 antibodies (Vli-55,
www.mmcri.org/antibody, Scarborough, ME, USA), rabbit
anti-IBA1 antibodies (#019-19741, Wako Chemicals USA
Inc., Richmond, VA, USA), rabbit anti-CDH11 antibodies
(WTID1, Invitrogen by Life Technologies, Grand Island,
NY, USA), and rabbit antibodies to smooth muscle actin
(α-SMA) (E184, Abcam, Cambridge, MA, USA). As a sec-
ondary antibody, donkey anti-rabbit antibodies conjugated
to HRP (Abcam, Cambridge, MA, USA) were used. After
three washes with PBST, slides were finally stained with
ImmPact 3,3′-diaminobenzidine (DAB) and counter-
stained with hematoxylin (Vector laboratories Inc.) or
alcian blue (Thermo Fisher Scientific Inc., Waltham, MA,
USA). Sections were dehydrated and mounted with
Permount (Thermo Fisher Scientific Inc.).
Recombinant protein overexpression
We used a full-length human Cthrc1 cDNA cloned in
frame with turbo-GFP (clone RG204348, OriGene Tech-
nologies, Inc., Rockville, MD, USA) as a template to
amplify a Cthrc1 sequence. High fidelity PCR using
Herculase II fusion DNA polymerase (Agilent Technologies,




to introduce sites for restriction endonucleases Kpn°I
and Hind°III and 6xHis tag and stop codon (restriction
sites are underlined; ATG and stop codons are bold-
faced; 6xHis coding sequence is italicized and under-
lined) for cloning the amplicon into the pCMV6-K/N
vector (OriGene Technologies, Inc.). The recombinant
construct structure was confirmed with a complete
sequencing (Thermo Fisher Scientific Inc., Fair Lawn,
NJ, USA).
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Transient transfection of the Chinese hamster ovary
(CHO) cells with lipofectamine LFA2000 was performed ac-
cording to the manufacturer’s protocol (Life Technologies,
Grand Island, NY, USA). CHO cells were grown in
Opti-CHO chemically-defined serum-free conditioned
media Opti-CHO (Gibco Life Technologies, Grand Island,
NY, USA) for 5 days. Conditioned media were collected
and centrifuged at 1000 × g for 15 minutes to separate
from floating cells.
Western immunoblotting
Cells were lysed in Laemmli sample buffer (62.5 mM Tris-
HCl, 2 % sodium dodecyl sulfate (SDS), 10 % glycerol,
0.05 % bromphenol blue, and 100 mM 2-mercaptoethanol).
Whole cell/tissue lysates were separated on 4–15 %
gradient SDS-polyacrylamide gels (Bio-Rad Laboratories
Inc., Hercules, CA, USA) and transferred onto polyvinyli-
dene fluoride membrane (Thermo Fisher Scientific Inc.,
Waltham, MA, USA). Membranes were blocked for 1 hour
in 1 % (w/v) casein in 25 mM Tris pH 7.4, 150 mM NaCl,
0.1 % Tween 20 (TBS-T) (casein blocking buffer, Thermo
Fisher Scientific Inc.). After blocking, the membranes were
probed with rabbit antibodies to CTHRC1 (Vli-55,
www.mmcri.org/antibody, Scarborough, ME, USA), rabbit
antibodies to CDH11 (Invitrogen Life Technologies, Grand
Island, NY, USA), rabbit antibodies to α-SMA (Abcam,
Cambridge, MA, USA), mouse antibodies to α-tubulin
(Sigma-Aldrich, St. Louis, MO, USA) as protein load con-
trol. As secondary antibodies, HRP-conjugated donkey
anti-rabbit, anti-mouse or anti-sheep antibodies (Abcam)
were used. Enhanced chemiluminescent substrate (Thermo
Fisher Scientific Inc.) and HyBlot-CL film (Denville
Scientific Inc., Holliston, MA, USA) were used to de-
tect a signal. Optical density was quantified by ImageJ
analysis software [19].
Cell migration assay
Cell migration was assessed using transwell permeable
supports with an 8-μm pore membrane (Corning Costar,
Tewksbury, MA, USA). C3H/10 T1/2 murine embryonic
fibroblasts or RA-FLS were seeded in the upper chamber
in DMEM supplemented with 1 % BSA. The lower
chamber was filled with DMEM containing 0 %, 1 %,
6 %, or 10 % FBS. rhCTHRC1 (Sino Biological Inc.,
Beijing, China) or rhCTHRC1 (OriGene Technologies
Inc., Rockville, MD, USA) were added to the upper
chamber at 500–2,000 ng/ml. After 18 hours at 37 °C in
5 % CO2, cells were fixed with 0.3 % glutaraldehyde in
PBS for 10 minutes at room temperature and then
stained with toluidine blue. Upper surface of the mem-
brane was cleaned to remove any non-migrated cells
using a cotton swab. Membranes were peeled off, and
mounted onto glass slides for microscopic examin-
ation. Transmigrated cells were counted at 200 ×
magnification in four to eight fields of view using
bright field microscopy.
Time-lapse microscopy
Murine NIH 3T3 fibroblasts were plated on collagen
type I-coated μ-slides (IBIDI USA Inc., Madison, WI)
and incubated for 4 hours at 37 °C in 5 % CO2/95 % air
in complete DMEM media supplemented with 10 % FBS
to insure complete cell adhesion on a bridge. Subse-
quently, rhCTHRC1 protein (Sino Biological Inc.,
Beijing, China) was added at 1000 ng/ml, and imaging
has been performed for 14 hours in a serum-containing
medium at 37 °C using time-lapse phase contrast mi-
croscopy with a Cell Observer microscope (Carl Zeiss
Microscopy GmbH, Göttingen, Germany). Recorded
stacks of images were transferred to ImageJ [19] and fur-
ther analyzed with the MTrackJ plugin and Chemotaxis
Tool (IBIDI USA Inc., Madison, WI, USA). The trajec-
tories of individual cells were evaluated for accumulated
distance migrated (Ad) and for cell velocity. Directness
was calculated as a ratio of Euclidean distance (Ed) to
the accumulated distance (Ed/Ad) (Fig. 6). Additionally,
elongated morphology cell shape was studied (horizontal
polarization), which was defined as maximal cell dimen-
sion using linear approximation. In preliminary experi-
ments, we found that pro-motile and polarization effects
of the CTHRC1 treatment were pronounced in the time
window from 4–12 hours, and thereafter all calculations
were performed for this time period.
Statistical analysis
Data were analyzed using Student’s t test for unpaired
samples, using SPSS statistical software (SPSS Inc.,
Chicago, IL, USA). The Mann–Whitney U test for un-
paired samples was performed using GraphPad Prism6
software (GraphPad Software Inc., La Jolla, CA, USA).
P-values less than 0.05 were considered significant.
Quantitative measurement of brown-colored DAB
product of IHC staining was performed using ImageJ
software [19] by color channel separation and densi-
tometry of microscopic images at × 200–400 magnifica-
tion. On each slide, at least five positively stained areas
were analyzed for integrated brown-colored density; at
least five slides per mouse (n = 5 per group) were
analyzed.
Results
CTHRC1 expression is strongly inducible in murine
arthritis
Earlier we reported low levels of Cthrc1 mRNA in the
paws of naïve mice, but substantial upregulation of
mRNA during inflammation [9]. To characterize which
tissue express CTHRC1, we used IHC staining of syn-
ovial joints. We induced arthritis in BALB/c mice using
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injections of anti-collagen antibodies followed by LPS
injections 3 days later. Using a standard protocol, we in-
duced strong inflammation in the paws of inbred BALB/
c mice and also in (FVB/N × BALB/c)F1 hybrids that are
less susceptible to CAIA. Arthritis was observed in the
form of swelling and redness of the fore and hind paws
of mice, and the diagnosis was confirmed using histo-
pathological analysis of hematoxylin-eosin-stained tissue
sections (Fig. 1). A thin synovial membrane in naïve
joints (Fig. 1a, c, green arrowheads) turned into a mas-
sively hypercellular pannus infiltrated with inflammatory
cells (Fig. 1b, d, yellow arrowheads). Polymorphonuclear
leukocytes were most abundant within the synovial
cavity and at the side of the pannus that was facing the
cavity (Fig. 1d, blue arrowheads), while pannus consisted
of fibrous-like large cells in contact with the bone sur-
face. Although the edema and redness was not visually
observable in larger joints, like the knee joint, the
histopathological examination showed the presence
of hyperplastic synovium and leukocyte infiltration.
IHC staining of the naïve synovial joints of hind paws
and knees was negative (Fig. 1e), while the amount of
CTHRC1 was dramatically increased in arthritis (Fig. 1f ).
We studied mice with early arthritis that had been
present for 2 days (5 days after mAb cocktail injection
or 2 days post-LPS injection) and also in mice that had
developed arthritis for 2 weeks. Joints of mice with early
and 2-week inflammation were equally positive for the
amount of CTHRC1 (Additional file 1). Protein was pre-
dominantly located in the hyperplastic pannus at the
bone/cartilage surface (Fig. 1f, yellow arrowheads).
The inducible pattern of the gene expression was corrob-
orated at the levels of RNA and protein. At the second day
after LPS injection we observed acute arthritis in mice, and
Cthrc1 mRNA was induced 11.9-fold (p < 0.0001), while the
corresponding protein increased 10.9-fold (p < 0.0018)
Fig. 1 Collagen triple helix repeat containing 1 (CTHRC1) expression is inducible in arthritis. Histology of hind limb (a, b) and knee joint (c–f)
sections of naïve and arthritic BALB/c mice. Ti tibia, Ta talus, N navicular bone of hind paw. In naïve mice, synovial membrane is normal (a, c, green
arrowheads). In mice with experimentally induced arthritis at the seventh day post injection of anti-collagen antibodies, massive multicellular pannus
(yellow arrowhead) and influx of granulocytes into synovial cavity (blue arrowhead) were prominent (b, d). Immunohistochemical staining for CTHRC1
was negative in the normal synovial membrane (e) in contrast to strong positive staining of the arthritic hyperplastic synovium (f, brown
3,3′-diaminobenzidine precipitate). The border between bone (Bn) and cartilage (Ct) is shown with a dashed line (f). Sections were counterstained
with hematoxylin (e, f) or stained with hematoxylin-eosin (a–d). Scale bars are 100 μm (a, b) and 50 μm (c–f). The data and images are representative
of the two independent experiments using BALB/c wildtype inbred mice and mice from (FVB/J × BALB/c)F1 hybrid genetic backgrounds
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(Fig. 2a, b). Western immunoblotting of the total protein
from naïve and arthritic paws confirmed that immune
staining was specific for the CTHRC1 polypeptide of the
predicted size (data not shown).
Peripheral blood of patients with RA contains high levels
of CTHRC1 protein
To corroborate the results based on murine arthritis,
and to show evidence for a possible role of CTHRC1 in
human RA, we collected clinical samples of blood
plasma from healthy individuals and from patients with
a diagnosis of RA. The average DAS28 in patients with
RA was 3.61 ± 0.72 (average ± standard deviation), and
the CRP concentration was 12.99 ± 14.91 mg/L (Fig. 2d,
e). In healthy individuals, CRP was significantly lower
(0.75 ± 0.86 mg/L) than in patients with RA (p < 0.0001,
Mann–Whitney U test). Circulating CTHRC1 was mea-
sured in both healthy and RA cohorts (median 2.00 ver-
sus 8.50, respectively, p < 0.0044, Mann–Whitney U test)
(Fig. 2c). Higher CTHRC1 in human plasma correlated
with increased CRP and stronger DAS28. In both the
murine arthritis model and in human arthritis, CTHRC1
protein was highly expressed compared to much lower
expression in normal/basal conditions.
Cells expressing CTHRC1 are located more frequently at
the pannus boundaries
IHC staining revealed several sites of the protein location in
arthritic synovium. CTHRC1 was expressed in cells located
closer to bone, cartilage, and fibrocartilage surfaces
(Fig. 3a–d). Intracellular protein expression was maximal in
cells in close contact with the bone and gradually decreased
towards the synovial cavity side of the pannus (Fig. 3b–d).
A similar pattern was observed in the knee joints and in
smaller joints of the hind paws. The intimal lining layer of
the pannus that faced synovial cavities was frequently
CTHRC1-positive (Fig. 3a, e, f). Some deposition of the
protein was detected on the bone surface (Fig. 3c, d), in
underlying synovial membrane connective tissue (Fig. 3e),
and in the areas adjacent to the bone/cartilage surface.
Fig. 2 Collagen triple helix repeat containing 1 (CTHRC1) expression is inducible both in mouse and in human arthritis. Naïve and arthritic mouse
paws were analyzed for Cthrc1 RNA message using RT-PCR of the total RNA isolated from paws of naïve mice and mice with collagen antibody-
induced arthritis (CAIA) (a). Protein content in synovium was measured using ImageJ densitometry of immunohistochemical-stained histological
sections (b). Student’s t test was used to estimate the difference between arthritic and naive groups. In patients with rheumatoid arthritis (RA)
with an average 28-joint-count disease activity score of 3.61 (e), blood plasma contained a significantly higher absolute concentration of CTHRC1
(c) and C-reactive protein (CRP) (d) according to the Mann–Whitney U test. Horizontal lines show median with range. Gapdh glyceraldehyde
3-phosphate dehydrogenase
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Specificity of the IHC staining was confirmed using
skeletal tissues of the Cthrc1-deficient mice generated
earlier [20]. Tissue sections were stained using pri-
mary and secondary antibodies, and the complete
IHC staining was negative (Fig. 3g). Similarly, negative
staining was achieved when primary anti-CTHRC1
antibodies Vli-55 were substituted with normal don-
key serum (Fig. 3h). IHC staining showed a similar
pattern for synovial tissues of two different genetic
backgrounds of the inbred BALB/c and (FVB/N ×
BALB/c)F1 hybrids.
Co-localization of cells expressing synoviocyte-specific
markers
CTHRC1-positive synoviocytes exhibited fibroblast-like
morphology and were located at the sites that are char-
acteristic for activated FLS (Figs. 1f, 3c–f ). We further
studied localization of cells expressing CTHRC1 and
Fig. 3 Immunohistochemical localization of collagen triple helix repeat containing 1 (CTHRC1) expressing cells in arthritic synovium. Immunohistochemical
staining (IHC) for CTHRC1 was positive for hypercellular pannus of the synovial joints of the hind paws (a) and of the knee (b–f) of BALB/c mice with
experimentally induced arthritis. Specificity of the IHC staining was confirmed using the complete staining protocol on Cthrc1 gene-deficient mouse skeletal
tissues (g). An additional control is shown using Cthrc1-wildtype tissue sections that were incubated with secondary donkey anti-rabbit antibody alone,
which produced no signal (h). CTHRC1+ cells were found in the arthritic pannus intimal lining (a, e, f) and at the bone-pannus and cartilage-pannus
boundaries (a–d). Dotted line shows the border between cartilage (Ct) and bone (Bn) (b). Fct fibrocartilage, Syn synovial cavity. Sections were counterstained
with alcian blue (c, d, g) or with hematoxylin (a, b, e, f, h). Scale bars are 100 μm (a), 50 μm (b, c, e, g, h), and 20 μm (d, f)
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their co-localization with fibroblast, myofibroblast, and
macrophage markers. For this purpose, we used median
sagittal histological sections of the knee (Fig. 4). Despite
the fact that larger knee joints are not the primary target
of arthritis in either human patients or mice, multicellu-
lar pannus was easy to find within knee joint synovium
upon routine histological examination (Fig. 4a, yellow
arrowheads). We used the meniscus as a landmark to
align and compare images (Fig. 4).
IBA1 is a calcium binding adaptor molecule also
known as allograft inflammatory factor 1 that is involved
in membrane ruffling and phagocytosis [21]. IBA1 is
expressed in activated macrophages and also in inflamed
synovium [22]. In mice with CAIA, IBA1+ macrophages
were infiltrating the entire pannus, but were more abun-
dant in synovial lining sides adjoining the synovial cavity
(intimal lining), and were basically absent at the area of
the bone-pannus interface (Fig. 4b, j). The size of the
IBA1+ cells was much smaller than large CTHRC1+
fibroblast-like cells. Dispersed IBA1+ staining contrasted
with CTHRC1 signal distribution.
Synovium was stained for α-SMA, which is expressed
in vascular smooth muscle cells and in myofibroblasts.
Expression of α-SMA is increased in the transition of
normal FLS to activated FLS [23]. In our experiments,
anti-α-SMA antibodies stained smooth muscle cells of
the vasculature of the naïve non-inflamed synovium
(data not shown), but IHC staining of synovial lining
and pannus was found only in CAIA (Fig. 4c, d, yellow
arrowhead). α-SMA+ cells were found mostly at the syn-
ovial intimal lining (Fig. 4c, d), and also at sites of the
pannus contacting fibrocartilage of the meniscus (Fig. 4l).
Vasculature was strongly positive for α-SMA (Fig. 4l).
CDH11 was previously established as one of the most
specific markers for activated FLS [2, 6]. In this CAIA
model, staining for CDH11 was most prominent in the
intimal lining (Fig. 4g, h), although any part of the pan-
nus, including the middle fibrous-like layer and the
bone-pannus interface contained CDH11+ cells (Fig. 4i).
Fig. 4 Co-localization of cells expressing synovial markers. Sagittal plane
histological sections of the medial aspect of inflamed knee joints were
stained with hematoxylin-eosin (a), macrophage-specific calcium-binding
protein IBA1 (b, j), alpha smooth muscle actin (α-SMA) (c, d, l), collagen
triple helix repeat containing 1 (CTHRC1) (e, f, k), cadherin CDH11 (g–i).
Sections were counterstained with hematoxylin or alcian blue. Meniscus
(m) was used to align images; femur (f), tibia (t). Area of the pannus-
meniscus junction labeled with yellow arrowheads (c, e, g) are zoomed in
at panels d, f, and h. Representative immunohistochemical (IHC) images
at panels i–l show the area of pannus-meniscus junction at higher × 40
objective magnification. At this structure, cells positive for CDH11,
CTHRC1 and α-SMA IHC staining demonstrated a similar gradient
distribution with maximal signal at the meniscus fibrocartilage-pannus
border, while macrophage-specific IBA1 showed dispersed localization.
Scale bars are 100 μm (a–h) and 25 μm (i–l)
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CTHRC1 IHC staining was found at the intimal lining
and the bone-pannus interface, locations that greatly
overlapped with sites of α-SMA and CDH11 expression
(Fig. 4c-l). Taking together, we found CTHRC1 protein
staining at several locations within the arthritic synovium.
The strongest signal was found in inflamed pannus with
some accumulation at the pannus borders represented by
the intimal lining and the bone/cartilage–pannus inter-
face. A much weaker and infrequent signal was found in
meniscus fibrocartilaginous cells in contact with the pan-
nus. Sometimes CTHRC1 positivity was found in liga-
ments and striated muscles, which could be remodeled
due to inflammation. Practically no IHC staining was
found in bone, articular cartilage, or growth plate chon-
drocytes (Figs. 1, 3, 4).
In brief, the conclusion of CTHRC1 synthesis by arth-
ritic pannus FLS is supported by (1) fibroblast-like
morphology of CTHRC1+ cells; (2) significant overlap
between CTHRC1+, CDH11+ and α-SMA+ staining;
and (3) no overlap with IBA1+ cell locations.
CTHRC1 promoted motility of embryonic fibroblasts and
RA-FLS
Overexpression of Cthrc1 transgene promoted migration
of cells from several lineages, including primary mouse
embryonic fibroblasts, smooth muscle and cancer cells
[13, 14]. The effect of CTHRC1 upon the cell motility of
activated synoviocytes and the more general effect in in-
flammatory conditions have never been studied.
We examined expression of CTHRC1 in murine fibro-
blasts and in RA-FLS using western immunoblotting.
Two lines of mouse embryonic fibroblasts NIH 3T3 and
Fig. 5 Collagen triple helix repeat containing 1 (CTHRC1) effects
transwell cell migration. (a) Western immunoblotting detection of
CTHRC1 in rheumatoid arthritis-fibroblast-like synoviocytes (RA-FLS),
NIH 3T3, C3H/10 T1/2. RA-FLS express CTHRC1, but murine fibroblasts
are negative for CTHRC1. (b) RA-FLS also express cadherin CDH11,
alpha smooth muscle actin (α-SMA), and α-tubulin. Staining membrane
with secondary antibodies alone was negative. (c) CTHRC1 is secreted
into conditioned media upon transfection and overexpression in Chin-
ese hamster ovary (CHO) cells. Lanes: (1) positive control 10 ng
rhCTHRC1; (2) day 0; (3) day 1; (4) day 3; (5) day 5. (d) RA-FLS were
treated directly in transwell chambers with rhCTHRC1 protein, while
FBS concentration was varied from 0 %, 1–6 %. Cells that migrated
through the membrane were stained with toluidine blue and counted
under the microscope. Solid black columns represent cells treated with
rhCTHRC1, gray columns are untreated cells. (e) murine C3H/10T1/2 fi-
broblasts were treated with rhCTHRC1 similarly to RA-FLS. (f) Serum
from mice with acute CAIA (5 % serum mixed with 5 % FBS in
complete media) showed the strongest promigratory effect. (g) Tolui-
dine blue staining and microscopy of cells migrated through the mem-
brane and spread on its opposite side after the completion of the
experiment. Numerous dots are membrane pores of 8 μm in size. Data
are representative of three similar but independent experiments. Statis-
tical significance was calculated using Student’s t test: *p < 0.05; **p <
0.01 for treatment versus no treatment comparison
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C3H/10T1/2 were studied, and both were negative for
CTHRC1 production (Fig. 5a). On the contrary, RA-FLS
were positive for CTHRC1 expression, and for cadherin
CDH11 and α-SMA production (Fig. 5b). This staining
of human synoviocytes paralleled IHC staining of the
mouse CAIA pannus (Fig. 4).
At IHC staining of inflamed synovial joints, some de-
position of CTHRC1 into bony and fibrocartilage tissues
was noticeable (Figs. 3, 4). Expression of CTHRC1 by
transiently transfected CHO cells in vitro and secretion
of the protein into media was confirmed (Fig. 5c). Re-
combinant human rhCTHRC1 is expressed intracellu-
larly in adherent cells with a peak at day 3 post
transfection. After centrifugation of the conditioned
media at 1000 × g for 15 minutes, protein was detectable
in the media supernatant as a single protein band at day
3 (Fig. 5c). CTHRC1 continued to accumulate in the
media until at least day 5, and there was no proteolytic
degradation of the secreted protein.
To study whether CTHRC1 has a promigratory effect
upon activated FLS and embryonic fibroblasts, we
treated cells with purified recombinant protein and
assayed cell motility using transwell plates. Neither RA-
FLS nor C3H/10T1/2 fibroblasts migrated in the absence
of serum even if CTHRC1 was provided (Fig. 5d, e),
hence, the CTHRC1 required serum components for
promoting cell motility. Cells were able to move through
the membrane in presence of 1–6 % FBS, and CTHRC1
demonstrated a positive effect on transwell cell motility
(1.4–5-fold, p < 0.05) (Fig. 5d, e). As a positive control,
we used serum taken from mice with CAIA. A mixture
of equal parts of arthritic serum and FBS (5 % arthritic
serum and 5 % FBS) in complete media showed the
strongest promigratory effect (Fig. 5f ). At the end of the
experiment, transmigrated fibroblasts had a normal mor-
phological spread (Fig. 5g).
To study detailed cellular mechanisms of motility pro-
moted by CTHRC1, we used time-lapse microscopy of
NIH 3T3 fibroblasts in specially designed μ-slide cham-
bers (IBIDI USA Inc., Madison, WI, USA). The μ-slide
bridge was coated with collagen type I. We treated fibro-
blasts with rhCTHRC1 at 200–1000 ng/ml in 10 % FBS
and monitored cells at the bridge using time-lapse mi-
croscopy for up to 14 hours. In these conditions that
were similar to those in the transwell assay experiment,
CTHRC1 also demonstrated a statistically significant
promigratory effect (Fig. 6). We traced trajectories of in-
dividual cells and combined them in Rose plots (Fig. 6a).
In the presence of CTHRC1, fibroblasts migrated a not-
ably longer distance on average, although the effect var-
ied greatly for individual cells. The velocity of cell
movement, directness and accumulated distance traveled
by cells all increased by 40 % (p < 0.01). The Euclidean
distance increased by 93 % (p < 0.05), which indicated
that in the presence of CTHRC1, fibroblasts were more
prone to maintaining a specific direction of migration
once it was selected by the cell.
Another clear effect of the treatment was the elong-
ation of cells or increase of cell size along the front-tail
axis. Cell size was measured between the front of the la-
mellipodium and the end of the cell tail (Fig. 6e). Upon
rhCTHRC1 treatment, NIH 3T3 fibroblast cell size was
significantly increased at 32 %, p < 0.01 (Fig. 6d, e). The
effect of cell elongation was obtained due to the protrac-
tion of the cell tail.
Discussion
In this study, we discovered that CTHRC1, otherwise a rec-
ognized marker of enhanced cancer metastases, is overex-
pressed in inflammatory conditions of murine arthritis.
Therefore, we corroborated our earlier transcriptome-based
finding that Cthrc1 mRNA is highly inducible in CAIA in-
flammation in synovial joints, and CTHRC1 protein con-
tent increases more than 10-fold within 3 days from a
basically undetectable level [9]. Due to clear inducibility in
arthritis, specificity for the arthritic pannus, and the ability
to be secreted into circulation, CTHRC1 could be a prom-
ising RA marker. In this study, the first pilot cohort of pa-
tients with RA had significantly increased circulating
CTHRC1 (Fig. 2c), and high CTHRC1 correlated with
increased CRP and with aggravated arthritis (Fig. 2d, e).
Interestingly, plasma CTHRC1 did not increase in patients
with solid tumors, where CTHRC1 is also strongly
expressed [7, 8, 16]. This discrepancy indicates that ways of
regulating CTHRC1 in the circulation might depend
on tissue vascularization, protein stability, and different/
other sites of protein production.
In synovium, CTHRC1 expression was detected at
multiple locations, while the major positive tissue was
pannus. Ligaments, muscles, and fibrocartilage were
sometimes positive for immunostaining, but more
studies are needed to understand why these sites are
affected. In general CTHRC1 is a marker of tissue re-
modeling, and inflammation or wounding could spark
its expression. The deposition of CTHRC1 in bone
and fibrocartilage at the sites of their contact with
pannus could be remnants of dead cells or could rep-
resent protrusions of FLS into bone. Synovial sites oc-
cupied with CTHRC1+ cells notably overlap with the
distribution of α-SMA+ cells. This overlap was de-
tected at the tissue (Fig. 4) and at the cellular levels
(Fig. 5b). Expression of α-SMA is a characteristic fea-
ture of stromal cells of different origin. In the recent
study of solid tumors, it was shown that CTHRC1 is
produced by a tumor stroma [15]. Activated FLS are
similar to stromal cells in their multipotency, i.e., the
ability to differentiate into chondrogenic and osteo-
genic lineages [1].
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Because of the clear correlation between the degree of
inflammation, and CTHRC1 mRNA and protein levels
and because the protein is expressed in fibroblast-like
cells, our first hypothesis was that CTHRC1 expression
promotes bone and cartilage erosion by activated FLS.
Nonetheless, we did not observe co-localization of FLS-
CTHRC1+ with sites of bone erosions. Also, CTHRC1+
cells comprised an intriguingly substantial portion of the
pannus (Fig. 1). An alternative hypothesis is that
CTHRC1 is labeling a remodeling tissue and mesenchy-
mal progenitor cells that influx into the arthritic syno-
vium to fight inflammation. In the CAIA murine model,
it is particularly obvious that this new pathologic tissue
of the pannus could not be formed due to the prolifera-
tion of normal FLS forming normal synovial membrane.
In CAIA, hypercellular pannus is formed within 2–3
Fig. 6 Time-lapse microscopy analysis of fibroblast migration under collagen triple helix repeat containing 1 (CTHRC1) treatment. NIH 3T3 fibroblasts
seeded onto μ-slides were treated with rhCTHRC1 at 1000 ng/ml and observed using time-lapse microscopy. (a) Cell trajectories derived from stacks of
images taken every 15 minutes during migration were presented as Rose plots to compare cell motility parameters. (b) Each cell trajectory was
analyzed for accumulated distance (Ad), Euclidean distance (Ed), directness (Ed/Ad), and cell velocity (Ad/time). (c) Average values for 20–40 cells for
each condition were compared. Solid black columns represent cells treated with rhCTHRC1, gray columns represent untreated cells. (d) Cell length was
defined as a Euclidean distance between the most distant points, usually between the front of lamellipodia and the end of cell tail. Cell length is
shown by a white bar. Phase contrast images of cells in the beginning and after 12 hours CTHRC1 treatment are presented. Scale bar is 20 μm.
(e) Cell length was measured at the beginning and the end of observation period. Data represent four similar but independent experiments. Statistical
significance was calculated using Student’s t test: *p < 0.05; **p < 0.01 for comparison of treatment versus no treatment
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days after induction. Therefore, CTHRC1+ FLS (or their
progenitors) have enough time only to migrate into the
synovial cavity and self-organize into new tissue within
the time frame of several days. In line with this hypoth-
esis, CTHRC1 was shown earlier to be a marker for
mesenchymal lineage cells, including osteoblasts and
RA-FLS [24]. The presence of mesenchymal stem/stromal
cells within the synovium has been demonstrated repeat-
edly [25–28].
Attempts to convert dermal fibroblasts or OA-FLS into
RA-FLS using stimulation with IL-1β or a mixture of pro-
inflammatory cytokines under hypoxia/normoxia were not
successful [29], which suggests that the pro-inflammatory
milieu is not sufficient to induce the de-differentiation of
FLS in arthritic joints, and normal FLS and RA-FLS are
somewhat different cell lineages. In this study, we found
abundant amounts of CTHRC1 in inflamed synovium,
which underlines the connection between inflammation
and stromal cell activation, although more research is
needed to prove that CTHRC1 is specific to synovial
stromal cells and to determine cellular targets of the pro-
motile activity of the protein. CTHRC1 increases cell
motility, and therefore promotes the influx of cells into in-
flamed joints and formation of the multicellular pannus.
The effect of CTHRC1 upon cell motility is manifold
and is not completely understood. Reports describe co-
precipitation of CTHRC1 with components of non-
canonical WNT signaling and stimulation of RhoA and
Rac1 phosphorylation [30, 31]. In hepatocellular car-
cinoma CTHRC1 promotes cell adhesion through acti-
vation of integrin β1 and phosphorylation of focal
adhesion kinase (FAK), while the activation of RhoA, but
not Rac1 or Cdc42 plays a crucial role [32].
In this study, we demonstrated a positive effect of
CTHRC1 upon motility of embryonic fibroblasts and
RA-FLS. Interestingly, the protein regulated cell mo-
tility in two ways: both directness and velocity. The
effect upon directness indicates that CTHRC1 induces
cell polarization via recruiting potential CTHRC1 sen-
sors/receptors at the leading edge of the lamelli-
podium. This effect of CTHRC1 might be connected
with the redistribution of WNT signaling receptors
and cell polarization (see also Fig. 6). The effect upon
velocity of movement is different from the regulation
of directness. The velocity effect should involve the
regulation of focal adhesion formation/disassembly
and stress fibers, and this is in line with CTHRC1
regulation of FAK and RhoA.
At this point, it is not clear whether CTHRC1 acts
from cytoplasm or via surface receptors, or both.
CTHRC1 siRNA approaches have been successfully used
to deregulate cell motility, but other studies, including
this one, effectively used exogenous CTHRC1 protein.
The effect of the addition of rhCTHRC1 into media with
murine fibroblasts lacking endogenous CTHRC1 sug-
gests the presence of surface receptors. In contrast, in RA-
FLS, which produce CTHRC1 endogenously, the mechan-
ism of cell motility regulation could use both intracellular
and extracelluar pathways.
Another possible mechanism of the regulation of cell
motility might involve the Gly-X-Y motif in CTHRC1
protein. This motif is actually a ligand involved in cell
adhesion by binding to α2β1 integrin [33–35]. Triple
helix motif-containing proteins, including CTHRC1,
might compete with collagens for cell adhesion recep-
tors and therefore attenuate cell adhesion onto the bone
surface, and, therefore, modulate cell motility. Recently,
a collagen-mimetic triple helical supramolecule contain-
ing the integrin-binding sequence was used to interfere
with α2β1 integrin-dependent cell adhesion [33]. Similar
approaches might have potential for intra-articular in-
terventions to control pannus activity and to treat
arthritis.
Conclusions
CTHRC1 was found in activated fibroblast-like synovio-
cytes in the inflamed synovium in murine arthritis and
in plasma from patients with RA. CTHRC1 is produced
by RA-FLS and increases its motility using an autocrine
loop, but the protein also has promigratory potential
upon other cells including fibroblasts that are not ter-
minally differentiated. CTHRC1 promoted fibroblast
polarization along the front-tail axis and increased the
speed of migration and directness of cell movement.
This promigratory effect on fibroblast-like synoviocytes
is one of the mechanisms in the hypercellularity of arth-
ritic pannus.
Additional file
Additional file 1: CTHRC1 and cadherin CDH11 expression in synovium
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medial aspect of inflamed knee joints were IHC stained for CTHRC1 (A, B)
and for cadherin CDH11 (C, D). Sections were prepared from arthritic
joints at day 4 (A, C) and 14 (B, D) of arthritis development. Histological
sections of the arthritic pannus-meniscal junction and meniscus (m) are
shown. Sections were counterstained with hematoxylin. (PDF 1154 kb)
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